Ariana Pelosci

In a phase 3 study, patients with biliary tract cancer who received adjuvant oral fluoropyrimidine derivative S-1 lived longer than patients who underwent surgery.

Compared to those who received rituximab and bendamustine, elderly patients treated with ibrutinib-containing regimens for chronic lymphocytic leukemia saw a progression-free survival benefit.

The costs of treatment and time spent managing adverse effects varied significantly in patients with chronic lymphocytic leukemia treated with acalabrutinib, ibrutinib, and venetoclax.

Compared to those who waited and received second line daratumumab-based regimens for transplant-ineligible newly diagnosed multiple myeloma, patients receiving daratumumab, lenalidomide, and dexamethasone in the first line saw better overall survival.

Improved invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status, was not improved with metformin, according to results of a phase 3 trial.